Un ensayo clínico allana el camino a un nuevo y revolucionario tratamiento de la miastenia grave
La FDA ha aprobado un nuevo medicamento para esta rara enfermedad neuromuscular.
Biopharmaceutical company UCB recently shared important news that may affect those living with generalized myasthenia gravis (gMG): they’ve received approval from the U.S. Food and Drug Administration (FDA) for a groundbreaking treatment called ZILBRYSQ® (zilucoplan).
The FDA approved Zilucoplan based on data from a study called RAISE, published in The Lancet Neurology in May 2023. The study showed that Zilucoplan offered rapid and significant benefits to a wide range of gMG patients.
Know Rare se enorgullece de haber apoyado este desarrollo reclutando pacientes para el Estudio RAISE. Una parte clave de la misión de Know Rare es ayudar a los pacientes que viven con enfermedades raras a conectarse con ensayos clínicos como éste que pueden tener un impacto positivo en su bienestar. Si está interesado en obtener más información sobre ensayos clínicos y estudios que podrían ser adecuados para usted, póngase en contacto con nosotros en support@knowrare.com.
MÁS SOBRE ZILBRYSQ® (zilucoplan):
Zilucoplan is a self-administered once-daily therapy for adults with generalized myasthenia gravis that works by inhibiting complement-mediated damage to the neuromuscular junction, which is where your nerves and muscles communicate. This helps to prevent the damage and weakness caused by myasthenia gravis. Unlike other treatments that need to be given intravenously, Zilucoplan is a subcutaneous (SC) peptide that you can inject under your skin. These developments mean that patients can take zilucoplan from their homes, reducing the need for frequent hospital visits.
